Company Information

  

Address: 343 OYSTER POINT BLVD #200  
City: SOUTH SAN FRANCISCO 
State: CA 
Zip Code: 94080 
Telephone: 650-870-1000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule oncology drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Tumor metabolism and immuno-oncology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. We are developing agents that take advantage of the unique metabolic requirements of tumor cells and cancer-fighting immune cells such as cytotoxic T-cells. Our lead product candidate, CB-839, is an internally discovered, first-in-class oral inhibitor of glutaminase, a critical enzyme in tumor cells. We are currently evaluating CB­839 in multiple Phase 1b/2 clinical trials in solid tumors.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-0.98NAN/E
06/2017-1.24NAN/E
03/2017-1.65NAN/E
12/2016-1.95NAN/E
09/2016-1.95NAN/E
06/2016-2.01NAN/E
03/2016-1.89NAN/E
12/2015-1.81NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.22Total Liab/Total Assets0.09
Net Inc/Total Assets-0.69Total Liab/Inv Cap0.10
Net Inc/Inv Cap-0.75Total Liab/Comm Equity0.03
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio12.03
Inventory TurnoverNACurrent Ratio12.03
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 7.25 7.26 4.19 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.07 2.85 3.31 3.01
Operating Income -6.65 -5.74 -5.76 -9.60
Interest Exp NA NA NA NA
Pretax Income -6.07 -5.19 -5.59 -9.52
Other Income 0.58 0.54 0.17 0.08
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -6.07 -5.19 -5.59 -9.52

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 165.61 166.23 155.33 51.78
Receivables - Total 2.18 2.30 13.55 NA
Inventories - Total NA NA NA NA
Total Current Assets 172.05 170.39 170.68 53.56
Net Property, Plant & Equipment 1.37 0.98 0.91 0.90
Total Assets 205.54 214.08 223.91 54.80
Liabilities        
Accounts Payable 8.41 5.42 4.83 4.45
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 37.42 34.43 33.84 4.45
Long-Term Debt NA NA NA NA
Total Liabilities 47.45 51.62 58.18 4.89
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -139.36 -133.29 -128.09 -122.50
Treasury Stock NA NA NA NA
Total Stockholders' Equity 158.09 162.46 165.73 49.91
Total Liabilities and Stockholders' Equity 205.54 214.08 223.91 54.80

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -11.31 1.17 35.25 -8.77
Net Cash Provided by Investing Activities -7.50 -32.62 -77.36 3.21
Net Cash Provided by Financing Activities 0.22 0.38 120.58 4.56

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-7.98--
12/20130.00-12.38--
12/20140.00-21.71-4.67
12/20150.00-32.64-1.81
12/20160.00-38.00-1.95
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1710925,63272.25




Report Date : 12/4/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.